AHRQ Comparative Effectiveness Reviews Will Expand Beyond Medicare
Executive Summary
The Agency for Healthcare Research & Quality is preparing to expand the scope of its comparative effectiveness reviews beyond the Medicare population
You may also be interested in...
PPIs Get AHRQ Stamp Of Approval Vs. Surgery; Generics Could Be Big Winners
The Agency for Healthcare Research & Quality's study on the effectiveness of proton pump inhibitors could lead to more difficulties for brand companies in seeking formulary placement
CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study
AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15